Savient to raise $53 million to fund gout treatment approval
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals expects to raise $52.9 million in net proceeds from a share offering, which it will use partly to fund efforts to gain FDA approval for its gout therapy Krystexxa (pegloticase). It is selling 4.3 million shares of common stock priced at $13.29 per share, and has granted its underwriters an over-allotment option of 645,000 additional shares.